Rentosertib, a drug candidate designed by Insilico Medicine using artificial intelligence, was the focus of a new paper published in Nature Biotechnology, as reported by Gizmodo.
Insilico Medicine uses AI to search for new active molecules and to develop drugs. The company has previously stated that rentosertib aims to treat patients with chronic lung disease and could potentially extend lifespan.
Trial design and findings
The small-scale clinical trial lasted 12 weeks and enrolled a total of 42 participants. Researchers used six different ageing-clock tests to assess changes in biological age — a measure of the body's physiological state relative to chronological age. According to the study, participants who received rentosertib showed reductions in biological age across those tests during the 12-week period, whereas the placebo group did not show similar shifts. All six applied clocks indicated an offset in the treated group.
Interpretation and limitations
Measures of biological age combine various biomarkers, such as blood test results, physiological measurements, and psychological test outcomes, to estimate how someone's body is ageing relative to their calendar age. The reported findings suggest rentosertib may have impacted these markers in the short term.
However, the trial was small, and the drug is far from being considered final or approved. Larger and longer-term studies are required, and the compound must still pass regulatory review before it could become available on the market.
Significance
That an AI-designed molecule produced short-term reductions in multiple biological ageing markers represents a notable step for AI-assisted drug discovery. Nonetheless, these results are preliminary: confirmation through further research is necessary to determine whether the observed effects are durable, mechanistically reproducible, and clinically meaningful.
